The latest biotech news

News and Trends 6 Apr 2017

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

Swiss Asceneuron has received regulatory approval to start its first Phase I trial of ASN120290, which is indicated for the treatment of dementia. Asceneuron was founded in 2012 as a spin-off of Merck Serono’s Alzheimer’s drug discovery portfolio. Its key asset ASN120290 is an inhibitor of the O-GlcNAcase enzyme and is indicated for the treatment of diseases associated […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 6 Apr 2017

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

UPDATE (06/04/2017): BerGenBio has raised €43.55M, successfully beating a biotech record on the Norwegian stock exchange and setting its market cap at €135M. UPDATE (28/03/2017): BerGenBio has announced that the IPO could run up to €44M on Oslo Børs. It could become the Norway stock exchange’s biggest IPO in biotech, and indeed €44M would make it […]

April 6, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 6 Apr 2017

How is Biotech Transforming Pharma’s R&D Model?

Since the early 2000s, pharma has undergone a major reorganization. What roles do strategic alliances and acquisitions play in this new model? For almost two centuries, medicinal products have brought continuous therapeutic progress. This path is marked by breakthrough innovations, which now allow us to treat diseases previously believed to be incurable. But to bring about […]

April 6, 2017 - 4 minutesmins - By External Contributor

Heptares AstraZeneka AZD4635 checkpoint inhibitor

News and Trends 5 Apr 2017

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Heptares Therapeutics has achieved a new milestone in its immuno-oncology collaboration with AstraZeneca triggering an €11M payment from AstraZeneca. Heptares has announced the wrap-up of its preclinical programme for a new checkpoint inhibitor, AZD4635 that reverses adenosine-mediated T cell suppression and enhances anti-tumor immunity. The British company will now receive an €11M ($12M) milestone payment from AstraZeneca, who obtained exclusive global rights […]

April 5, 2017 - 3 minutesmins - By Melanie De Almeida

News and Trends 5 Apr 2017

Planning a Clinical Trial – Think Smart Design

By using smart designs, sponsors can save time and money while optimizing the knowledge accrued during the development of their products. “Traditional” study designs and statistical methodology do not allow changing the main features of a study protocol once the study has been initiated. The use of interim analyses, and in particularly the development of […]

April 5, 2017 - 5 minutesmins - By External Contributor

News and Trends 4 Apr 2017

Sample a More Efficient Sorbent to Streamline your mAb Purification

Need an efficient way to purify your antibodies but struggle to find the best column? Pall Life Sciences is giving you the opportunity to try their solution for free. Enter your email below and receive your KANEKA Protein A sorbent sample! Pall Life Sciences is giving you a chance to try for free the new, […]

April 4, 2017 - 2 minutesmins - By External Contributor

News and Trends 3 Apr 2017

Massive €800M Acquisition of Belgian Biotech treating Menopause

Astellas Pharma is acquiring Ogeda, getting hold of its promising Phase II candidate to treat menopause without hormonal therapy. After acquiring Ganymed Pharmaceuticals last October for a record €1.3B in German biotech, the Japanese Astellas Pharma is making a second massive acquisition in Europe. Its new addition is Ogeda, a Belgian biotech targeting GPCRs to treat gynecological […]

April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Apr 2017

New Results Show GM Mosquitoes Keep Dengue and Zika at Bay in Brazil

In its second year, Oxitec has reduced the mosquito population in a Brazilian neighborhood by 81%, demonstrating the long-term potential of GM insects. Oxitec is a spin-out from the University of Oxford that fights infectious disease with genetically-engineered mosquitoes that produce inviable offspring. The company has already made field trials in the Cayman Islands, Panama, Brazil, […]

April 3, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

News and Trends 3 Apr 2017

UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today

GSK has punched a hole in the glass ceiling with its appointment of a new female CEO, Emma Walmsley. It’s up to her to reinvigorate the company. Emma Walmsley may be the most powerful woman in corporate Britain. The Oxford grad and L’Oreal veteran has just been crowned CEO of the pharma giant GSK: a marketing […]

April 3, 2017 - 2 minutesmins - By Evelyn Warner

News and Trends 31 Mar 2017

French Synbio Company gets ready to break into Cosmetics

After biofuels and carotenoids, Deinove is now moving forward on the cosmetics front. Its engineered microbes can produce a number of interesting chemicals for skin care, and Deinove plans to bring them to market until the end of 2018. Deinove is a key synbio biotech in France and has found a wide range of applications for […]

March 31, 2017 - 3 minutesmins - By Denise Neves Gameiro

News and Trends 30 Mar 2017

New Clues on How the Immune System Weakens with Age

By analyzing the responses of individual immune cells, a new study in Science provides new insights into the decline of the immune system with age. In a collaborative effort, researchers from the European Bioinformatics Institute (EMBL-EBI), University of Cambridge, the Wellcome Trust Sanger Institute and the Cancer Research UK–Cambridge Institute (CRUK-CI) have shed light on a […]

March 30, 2017 - 2 minutesmins - By Melanie De Almeida

News and Trends 30 Mar 2017

Merck Outsources the Development of its Nanobody for Psoriasis

Merck has signed a new agreement with Avillion for its nanobody against psoriasis. Avillion will advance the nanobody from Phase II through Phase III. As part of several partnerships between Merck and the unbeaten nanobody biotech Ablynx, Merck recently cleared Phase Ib with its llama-inspired nanobody targeting the cytokines IL-17 A/F for the treatment of plaque psoriasis. The antibody […]

March 30, 2017 - 3 minutesmins - By Melanie De Almeida

Resources

Categories

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

Approaches

Therapeutic areas

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The twelve hottest biotech companies in the Boston area

Biotech bankruptcies: what to expect in 2024 following a record year?

RNA editing set to take off: could it outperform gene editing?

Future of cancer treatment: what will therapy look like in 2034?

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

Biotech Targeting Tau-Tangles in Neurodegeneration Initiates Clinical Trials

UPDATE: Norwegian Stock Exchange hits Record Biotech IPO

How is Biotech Transforming Pharma’s R&D Model?

Heptares Takes Home €11M for its Next-Generation Checkpoint Inhibitor

Planning a Clinical Trial – Think Smart Design

Sample a More Efficient Sorbent to Streamline your mAb Purification

Massive €800M Acquisition of Belgian Biotech treating Menopause

New Results Show GM Mosquitoes Keep Dengue and Zika at Bay in Brazil

UPDATE: First Woman CEO of a Global Drug Maker starts at GSK today

French Synbio Company gets ready to break into Cosmetics

New Clues on How the Immune System Weakens with Age

Merck Outsources the Development of its Nanobody for Psoriasis

Subscribe to our newsletter to get the latest biotech news!